

# David E Neal

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5283346/david-e-neal-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

371  
papers

24,959  
citations

78  
h-index

146  
g-index

395  
ext. papers

28,956  
ext. citations

8.3  
avg, IF

6.15  
L-index

#	Paper	IF	Citations
371	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. <i>Scientific Reports</i> , <b>2021</b> , 11, 9264	4.9	3
370	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , <b>2021</b> , 53, 65-75	36.3	62
369	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 532-541	6.2	3
368	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , <b>2021</b> , 12, 1236	17.4	14
367	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , <b>2021</b> , 4, 570-579	6.7	12
366	A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. <i>World Journal of Urology</i> , <b>2021</b> , 1	4	1
365	MenQ experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. <i>Cancer Causes and Control</i> , <b>2021</b> , 32, 261-269	2.8	3
364	The Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
363	Independence of HIF1a and androgen signaling pathways in prostate cancer. <i>BMC Cancer</i> , <b>2020</b> , 20, 469	4.8	8
362	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , <b>2020</b> , 28, 1467-1475	5.3	5
361	Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. <i>Cancer Causes and Control</i> , <b>2020</b> , 31, 431-449	2.8	24
360	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 1731-1738	4	14
359	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , <b>2020</b> , 24, 1-176	4.4	9
358	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , <b>2020</b> , 125, 506-514	5.6	14
357	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , <b>2020</b> , 77, 320-330	10.2	50
356	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1063-1070	8.7	4
355	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , <b>2020</b> , 10, e036024	3	1

354	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3244-3256	7.5	9
353	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , <b>2019</b> , 113, 200-213	5.7	2
352	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. <i>European Urology</i> , <b>2019</b> , 76, 329-337	10.2	28
351	Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial. <i>European Journal of Cancer Prevention</i> , <b>2019</b> , 28, 569-575	2	4
350	Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , <b>2019</b> , 48, 1416-1424	7.8	24
349	A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. <i>Cancer Research</i> , <b>2019</b> , 79, 274-285	10.1	17
348	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 208-216	4	9
347	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. <i>Oncogene</i> , <b>2019</b> , 38, 1136-1150	9.2	12
346	Identification of potential therapeutic targets in prostate cancer through a cross-species approach. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	20
345	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 883-895	27.4	184
344	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <i>Cancer Epidemiology</i> , <b>2018</b> , 52, 99-105	2.8	4
343	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. <i>Journal of Urology</i> , <b>2018</b> , 199, 1470-1474	2.5	8
342	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , <b>2018</b> , 50, 682-692	36.3	112
341	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. <i>Cancer Causes and Control</i> , <b>2018</b> , 29, 383-388	2.8	9
340	Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). <i>European Journal of Oncology Nursing</i> , <b>2018</b> , 32, 73-81	2.8	12
339	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , <b>2018</b> , 96, 35-46	5.7	9
338	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ, The</i> , <b>2018</b> , 360, j5757	5.9	85
337	DESNT: A Poor Prognosis Category of Human Prostate Cancer. <i>European Urology Focus</i> , <b>2018</b> , 4, 842-850	5.1	18

336	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , <b>2018</b> , 50, 928-936	36.3	340
335	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , <b>2018</b> , 9, 2256	17.4	57
334	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , <b>2018</b> , 9, 4616	17.4	30
333	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. <i>Cancer Prevention Research</i> , <b>2018</b> , 11, 687-696	3.2	21
332	Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 1881-1887	7.5	13
331	Asporin is a stromally expressed marker associated with prostate cancer progression. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 775-784	8.7	26
330	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. <i>European Urology</i> , <b>2017</b> , 72, 509-518	10.2	14
329	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. <i>PLoS Genetics</i> , <b>2017</b> , 13, e1007001	6	20
328	Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 374	17.4	99
327	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 734-743	8.7	5
326	Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment ( ProtecT) trial. <i>Cancer Causes and Control</i> , <b>2017</b> , 28, 877-888	2.8	2
325	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 322-328	7.5	13
324	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , <b>2017</b> , 72, 22-31	10.2	28
323	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. <i>Journal of Urology</i> , <b>2017</b> , 197, 607-613	2.5	13
322	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , <b>2017</b> , 71, 381-388	10.2	25
321	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 75-85	7.5	22
320	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. <i>BMJ Open</i> , <b>2017</b> , 7, e017729	3	16
319	Validation of the Hospital Episode Statistics Outpatient Dataset in England. <i>Pharmacoeconomics</i> , <b>2016</b> , 34, 161-8	4.4	15

318	Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, 797-812	5.7	11
317	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1415-1424	59.2	1451
316	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1425-1437	59.2	655
315	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. <i>BJU International</i> , <b>2016</b> , 118, 869-879	5.6	38
314	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1052-67	24.4	104
313	Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?. <i>Cancer Causes and Control</i> , <b>2016</b> , 27, 1465-1474	2.8	14
312	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , <b>2016</b> , 7, 10979	17.4	37
311	Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 90-4	8.7	31
310	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. <i>Trials</i> , <b>2016</b> , 17, 497	2.8	3
309	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , <b>2016</b> , 14, 66	11.4	29
308	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. <i>Statistical Methods in Medical Research</i> , <b>2016</b> , 25, 1875-1891	2.3	5
307	Misclassification of outcome in case-control studies: Methods for sensitivity analysis. <i>Statistical Methods in Medical Research</i> , <b>2016</b> , 25, 2377-2393	2.3	14
306	Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 1008-18	5.6	18
305	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , <b>2016</b> , 76, 2288-2300	10.1	85
304	Gene regulatory mechanisms underpinning prostate cancer susceptibility. <i>Nature Genetics</i> , <b>2016</b> , 48, 387-97	36.3	72
303	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 945-52	8.7	13
302	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	27
301	The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 214-8	10.2	47

300	HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 74734-74746	3.3	31
299	A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. <i>Oncotarget</i> , <b>2016</b> , 7, 21393-403	3.3	17
298	Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre. <i>BJU International</i> , <b>2016</b> , 118, 779-784	5.6	12
297	Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts. <i>BJU International</i> , <b>2016</b> , 118, 911-918	5.6	5
296	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , <b>2016</b> , 53, 800-811	5.8	121
295	Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). <i>BMJ Open</i> , <b>2016</b> , 6, e011063	3	20
294	Response of Degarelix treatment in human prostate cancer monitored by HR-MAS H NMR spectroscopy. <i>Metabolomics</i> , <b>2016</b> , 12, 120	4.7	24
293	Circulating Folate and Vitamin B and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. <i>European Urology</i> , <b>2016</b> , 70, 941-951	10.2	36
292	Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer. <i>Molecular and Cellular Oncology</i> , <b>2016</b> , 3, e1140262	1.2	2
291	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 716-22	5.7	24
290	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 1520-33	7.5	18
289	Blood lipids and prostate cancer: a Mendelian randomization analysis. <i>Cancer Medicine</i> , <b>2016</b> , 5, 1125-36	4.8	45
288	Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. <i>BJU International</i> , <b>2016</b> , 117, E10-9	5.6	90
287	Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 620-635	6.6	31
286	Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial Lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer). <i>BMC Medical Research Methodology</i> , <b>2015</b> , 15, 6	4.7	7
285	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 1121-9	4	46
284	A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. <i>Journal of Pathology</i> , <b>2015</b> , 236, 517-30	9.4	77
283	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. <i>BMC Health Services Research</i> , <b>2015</b> , 15, 80	2.9	10

282	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , <b>2015</b> , 25, 814-24	9.7	52
281	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. <i>Nature Genetics</i> , <b>2015</b> , 47, 367-372	36.3	292
280	HES5 silencing is an early and recurrent change in prostate tumourigenesis. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, 131-44	5.7	8
279	Surgical margin length and location affect recurrence rates after robotic prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 109.e7-13	2.8	46
278	The evolutionary history of lethal metastatic prostate cancer. <i>Nature</i> , <b>2015</b> , 520, 353-357	50.4	857
277	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , <b>2015</b> , 26, 1603-16	2.8	56
276	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 5589-602	5.6	54
275	Gleason drift in the NIHR ProtecT study. <i>Histopathology</i> , <b>2015</b> , 66, 438-46	7.3	9
274	Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. <i>American Journal of Clinical Nutrition</i> , <b>2015</b> , 102, 1142-57	7	89
273	Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	116
272	Genome-wide association study of prostate cancer-specific survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 1796-800	4	23
271	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. <i>Genetics in Medicine</i> , <b>2015</b> , 17, 789-95	8.1	70
270	Selective Targeting of the TPX2 Site of Importin- $\beta$ Using Fragment-Based Ligand Design. <i>ChemMedChem</i> , <b>2015</b> , 10, 1232-9	3.7	10
269	Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. <i>BMJ Open</i> , <b>2015</b> , 5, e008953	3	15
268	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , <b>2015</b> , 75, 1467-74	4.4	43
267	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 736-45	36.3	306
266	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. <i>Nature Communications</i> , <b>2015</b> , 6, 6605	17.4	245
265	Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: opportunities for lifestyle modification. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 1509-15	7.5	19

264	Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. <i>Cancer Causes and Control</i> , <b>2015</b> , 26, 205-218	2.8	28
263	Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature. <i>BJU International</i> , <b>2015</b> , 115, 698-704	5.6	20
262	Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. <i>European Urology</i> , <b>2015</b> , 67, 993-1005	10.2	75
261	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. <i>Cancer Discovery</i> , <b>2015</b> , 5, 368-79	24.4	41
260	Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136735	3.7	5
259	Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 21675-84	3.3	20
258	Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study. <i>Health Services and Delivery Research</i> , <b>2015</b> , 3, 1-138	1.5	3
257	Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. <i>Cancer Research</i> , <b>2014</b> , 74, 896-907	10.1	92
256	Regulation of the localisation and function of the oncogene LYRIC/AEG-1 by ubiquitination at K486 and K491. <i>Molecular Oncology</i> , <b>2014</b> , 8, 633-41	7.9	4
255	Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. <i>EMBO Journal</i> , <b>2014</b> , 33, 1365-82	13	48
254	Late Imaging with [1-(11)C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1144-9	8.9	19
253	Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , <b>2014</b> , 345, 1251343	33.3	250
252	Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences. <i>Trials</i> , <b>2014</b> , 15, 323	2.8	41
251	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , <b>2014</b> , 46, 1103-9	36.3	331
250	The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. <i>BMC Family Practice</i> , <b>2014</b> , 15, 81	2.6	30
249	Key considerations for the experimental training and evaluation of cancer odour detection dogs: lessons learnt from a double-blind, controlled trial of prostate cancer detection. <i>BMC Urology</i> , <b>2014</b> , 14, 22	2.2	63
248	Design and preliminary recruitment results of the Cluster randomised trial of PSA testing for Prostate cancer (CAP). <i>British Journal of Cancer</i> , <b>2014</b> , 110, 2829-36	8.7	23
247	A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. <i>European Urology</i> , <b>2014</b> , 66, 450-6	10.2	85



246	Estrogen receptor beta in prostate cancer: friend or foe?. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, T219-34	5.7	68
245	Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e110569	3.7	17
244	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. <i>ELife</i> , <b>2014</b> , 3,	8.9	229
243	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1521-1532	21.7	218
242	Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004129	6	30
241	PROSPECTIV-a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial. <i>BMJ Open</i> , <b>2014</b> , 4, e005186 <sup>3</sup>		8
240	Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. <i>BMJ Open</i> , <b>2014</b> , 4, e004285	3	28
239	Adherence to dietary and lifestyle recommendations and prostate cancer risk in the prostate testing for cancer and treatment ( ProtecT) trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2066-77	4	27
238	HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. <i>EMBO Molecular Medicine</i> , <b>2014</b> , 6, 651-61	12	45
237	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1109-18	21.7	157
236	The ETS family member GABPA modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. <i>Nucleic Acids Research</i> , <b>2014</b> , 42, 6256-69	20.1	26
235	Men's knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. <i>BMC Cancer</i> , <b>2014</b> , 14, 812	4.8	13
234	Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 1356-1365	4.1	24
233	The transcriptional programme of the androgen receptor (AR) in prostate cancer. <i>BJU International</i> , <b>2014</b> , 113, 358-66	5.6	24
232	Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , <b>2014</b> , 32, 185-91	4	23
231	Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. <i>Oncotarget</i> , <b>2014</b> , 5, 3785-99	3.3	14
230	Method for sampling tissue for research which preserves pathological data in radical prostatectomy. <i>Prostate</i> , <b>2013</b> , 73, 194-202	4.2	16
229	Men with prostate cancer make positive dietary changes following diagnosis and treatment. <i>Cancer Causes and Control</i> , <b>2013</b> , 24, 1119-28	2.8	30

228	Prostate Cancer UK: the Blue Skies Forum. <i>Trends in Urology &amp; Mens Health</i> , <b>2013</b> , 4, 39-43	0.3	1
227	The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. <i>Cancer Cell</i> , <b>2013</b> , 23, 35-47	24.3	282
226	Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. <i>BJU International</i> , <b>2013</b> , 111, 1148-55	5.6	7
225	Very low PSA concentrations and deletions of the KLK3 gene. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 234-44	5.5	10
224	Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. <i>Cancer Causes and Control</i> , <b>2013</b> , 24, 39-45	2.8	8
223	Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. <i>Cancer Causes and Control</i> , <b>2013</b> , 24, 323-34	2.8	27
222	Predictors of the use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: data from a pilot study of 1756 cases 2004-2011. <i>BJU International</i> , <b>2013</b> , 111, 1061-7	5.6	3
221	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , <b>2013</b> , 45, 385-91, 391e1-2	36.3	413
220	Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 635-43	2.8	25
219	Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer. <i>Biochemistry</i> , <b>2013</b> , 52, 1429-36	3.2	21
218	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 408-15	5.6	109
217	The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 126-39	5	45
216	Androgen deprivation treatment in prostate cancer. <i>BMJ, The</i> , <b>2013</b> , 346, e8555	5.9	11
215	Global assessment of network inference algorithms based on available literature of gene/protein interactions. <i>Turkish Journal of Biology</i> , <b>2013</b> , 37, 547-555	3.1	10
214	Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4235-41	2.2	60
213	A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 5056-64	5.6	107
212	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 2520-8	5.6	88
211	Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin d and prostate cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 597-606	4	19

210	Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. <i>European Journal of Cancer Prevention</i> , <b>2013</b> , 22, 121-5	2	7
209	Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 2176-85	7.5	27
208	The role of 1.5 Tesla magnetic resonance imaging in staging prostate cancer. <i>ANZ Journal of Surgery</i> , <b>2013</b> , 83, 234-8	1	15
207	Role of the androgen receptor in prostate cancer. <i>Trends in Urology &amp; Men's Health</i> , <b>2013</b> , 4, 26-30	0.3	
206	The first national clinical audit of prostate cancer care. <i>BJU International</i> , <b>2013</b> , 112, 883-4	5.6	2
205	The role of surgery in high-risk localised prostate cancer. <i>BJU International</i> , <b>2012</b> , 109, 648-58	5.6	23
204	Detailed analysis of operating time learning curves in robotic prostatectomy by a novice surgeon. <i>BJU International</i> , <b>2012</b> , 109, 1074-80	5.6	16
203	General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. <i>BJU International</i> , <b>2012</b> , 110, 24-7	5.6	7
202	Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. <i>Cancer Causes and Control</i> , <b>2012</b> , 23, 347-54	2.8	30
201	Evaluating genetic risk for prostate cancer among Japanese and Latinos. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 2048-58	4	46
200	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. <i>Nature Genetics</i> , <b>2012</b> , 44, 1326-9	36.3	151
199	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , <b>2012</b> , 30, 181-7	4	50
198	Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. <i>Cancer Causes and Control</i> , <b>2012</b> , 23, 1865-73	2.8	19
197	Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy. <i>European Urology</i> , <b>2012</b> , 62, 649-55	10.2	20
196	RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. <i>Neoplasia</i> , <b>2012</b> , 14, 476-86	6.4	128
195	The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. <i>International Journal of Cancer</i> , <b>2012</b> , 131, E179-89	7.5	69
194	Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 1187-96	7.5	55
193	Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. <i>Cancer Causes and Control</i> , <b>2012</b> , 23, 575-88	2.8	20

192	A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. <i>Cancer Causes and Control</i> , <b>2012</b> , 23, 907-17	2.8	30
191	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , <b>2012</b> , 30, 149-55	4	81
190	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , <b>2012</b> , 31, 1617-1617	13	1
189	Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. <i>Cancer Research</i> , <b>2012</b> , 72, 503-15	10.1	44
188	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. <i>BMJ, The</i> , <b>2012</b> , 344, d7894	5.9	163
187	Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 1877-85	4	15
186	Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 11252-7	11.5	82
185	No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses. <i>PLoS ONE</i> , <b>2012</b> , 7, e34221	3.7	16
184	Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. <i>Neoplasia</i> , <b>2011</b> , 13, 887-98	6.4	75
183	Growing Teratoma Syndrome: A Case of Mistaken Identity. <i>British Journal of Medical and Surgical Urology</i> , <b>2011</b> , 4, 272-275		
182	Differential C3NET reveals disease networks of direct physical interactions. <i>BMC Bioinformatics</i> , <b>2011</b> , 12, 296	3.6	28
181	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , <b>2011</b> , 43, 1098-103	36.3	203
180	Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. <i>Neoplasia</i> , <b>2011</b> , 13, 676-84	6.4	97
179	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. <i>Journal of Clinical Epidemiology</i> , <b>2011</b> , 64, 628-36	5.7	17
178	Exploring treatment preferences facilitated recruitment to randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , <b>2011</b> , 64, 1127-36	5.7	73
177	First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single UK centre: learning curves of two surgeons. <i>BJU International</i> , <b>2011</b> , 108, 739-47	5.6	36
176	Trends in the use of radiotherapy and radical surgery for patients with bladder urothelial cell carcinoma in East Anglia, 1995-2006. <i>BJU International</i> , <b>2011</b> , 108, 1106-14	5.6	6
175	Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. <i>BJU International</i> , <b>2011</b> , 108, 1402-8	5.6	46

174	Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. <i>BJU International</i> , <b>2011</b> , 108, 1409-14	5.6	6
173	Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 875-81	8.7	20
172	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. <i>EMBO Journal</i> , <b>2011</b> , 30, 2719-33	13	423
171	Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections. <i>BJU International</i> , <b>2011</b> , 108, 1597-602	5.6	24
170	Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. <i>Human Genetics</i> , <b>2011</b> , 129, 687-94	6.3	72
169	Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. <i>Molecular Cancer</i> , <b>2011</b> , 10, 65	42.1	79
168	Prostate cancer metabolite quantification relative to water in <sup>1</sup> H-MRSI in vivo at 3 Tesla. <i>Magnetic Resonance in Medicine</i> , <b>2011</b> , 65, 914-9	4.4	22
167	Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 574-86	7.5	353
166	Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). <i>International Journal of Cancer</i> , <b>2011</b> , 128, 440-6	7.5	53
165	Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 562-73	7.5	214
164	Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). <i>International Journal of Cancer</i> , <b>2011</b> , 128, 1442-8	7.5	35
163	PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 1462-70	7.5	13
162	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. <i>Cancer Epidemiology</i> , <b>2011</b> , 35, 139-44	2.8	4
161	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. <i>Nature Genetics</i> , <b>2011</b> , 43, 785-91	36.3	243
160	Genome-wide association study identifies new prostate cancer susceptibility loci. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 3867-75	5.6	143
159	The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 2051-61	3.2	58
158	Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1090-8	12.9	82
157	Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. <i>British Journal of Cancer</i> , <b>2011</b> , 105, 931-7	8.7	15

156	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , <b>2011</b> , 30, 3019-27	13	203
155	Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. <i>PLoS ONE</i> , <b>2011</b> , 6, e26527	3.7	11
154	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. <i>International Journal of Molecular Epidemiology and Genetics</i> , <b>2011</b> , 2, 316-27	0.9	9
153	Pre-malignant Disease in the Prostate <b>2011</b> , 467-491		
152	The Development of a Robotic Urology Program in the UK <b>2011</b> , 97-109		
151	Mutation analysis of the MSMB gene in familial prostate cancer. <i>British Journal of Cancer</i> , <b>2010</b> , 102, 4148-57	19	
150	Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. <i>British Journal of Cancer</i> , <b>2010</b> , 102, 1335-40	8.7	60
149	Enhanced recovery: from principles to practice in urology. <i>BJU International</i> , <b>2010</b> , 105, 1199-201	5.6	8
148	The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. <i>PLoS ONE</i> , <b>2010</b> , 5, e13363	3.7	68
147	Genetic correction of PSA values using sequence variants associated with PSA levels. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 62ra92	17.5	125
146	Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 2833-8	4	20
145	The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4374-81	12.9	72
144	Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey. <i>BMJ, The</i> , <b>2010</b> , 340, c1928	5.9	37
143	RAS pathways in prostate cancer - mediators of hormone resistance?. <i>Current Cancer Drug Targets</i> , <b>2010</b> , 10, 834-9	2.8	9
142	Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 1632-42	4	116
141	Overexpression of the JmJc histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. <i>Molecular Cancer</i> , <b>2010</b> , 9, 59	42.1	154
140	Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 943-54	5.8	50
139	PSA testing for prostate cancer improves survival--but can we do better?. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 702-3	21.7	10

138	Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. <i>Biochemical Journal</i> , <b>2010</b> , 428, 439-50	3.8	135
137	Where are we now with prostate cancer diagnosis?. <i>Trends in Urology &amp; Men's Health</i> , <b>2010</b> , 1, 18-20	0.3	2
136	The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. <i>Cancer Causes and Control</i> , <b>2010</b> , 21, 1829-42	2.8	23
135	Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. <i>European Urology</i> , <b>2010</b> , 57, 446-52	10.2	12
134	The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. <i>Prostate</i> , <b>2010</b> , 70, 333-40	4.2	48
133	Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. <i>PLoS ONE</i> , <b>2010</b> , 5, e10858	3.7	24
132	Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. <i>PLoS ONE</i> , <b>2010</b> , 5, e13485	3.7	46
131	A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). <i>International Journal of Molecular Epidemiology and Genetics</i> , <b>2010</b> , 1, 175-83	0.9	11
130	PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2009</b> , 12, 296-300	6.2	15
129	Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 1198-204	8.7	48
128	A recurrent truncating germline mutation in the BRIP1/FANCD1 gene and susceptibility to prostate cancer. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 426-30	8.7	44
127	Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. <i>Journal of Health Services Research and Policy</i> , <b>2009</b> , 14, 77-81	2.4	13
126	Stage shift in PSA-detected prostate cancers - effect modification by Gleason score. <i>Journal of Medical Screening</i> , <b>2009</b> , 16, 98-101	1.4	15
125	LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3003-13	12.9	67
124	Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 2874-81	4	60
123	Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 2528-39	4	75
122	It's not just what you say, it's also how you say it: opening the black box of informed consent appointments in randomised controlled trials. <i>Social Science and Medicine</i> , <b>2009</b> , 68, 2018-28	5.1	127
121	Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 1414-23	7.5	43

120	Identification of new genetic risk factors for prostate cancer. <i>Asian Journal of Andrology</i> , <b>2009</b> , 11, 49-55	2.8	20
119	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. <i>Nature Genetics</i> , <b>2009</b> , 41, 1116-21	36.3	360
118	Multiple loci on 8q24 associated with prostate cancer susceptibility. <i>Nature Genetics</i> , <b>2009</b> , 41, 1058-60	36.3	252
117	Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. <i>British Journal of Cancer</i> , <b>2009</b> , 101, 390-4	8.7	15
116	Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. <i>BJU International</i> , <b>2009</b> , 104, 1592-8	5.6	63
115	Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 2569-73	7.5	15
114	Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 3254-61	7.5	9
113	Psychological distress and prostate specific antigen levels in men with and without prostate cancer. <i>Brain, Behavior, and Immunity</i> , <b>2009</b> , 23, 1073-8	16.6	6
112	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. <i>Journal of Clinical Epidemiology</i> , <b>2009</b> , 62, 29-36	5.7	121
111	Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. <i>Journal of Clinical Epidemiology</i> , <b>2009</b> , 62, 67-73	5.7	11
110	Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. <i>ACS Chemical Biology</i> , <b>2009</b> , 4, 503-25	4.9	65
109	Screening for prostate cancer remains controversial. <i>Lancet, The</i> , <b>2009</b> , 374, 1482-3	40	19
108	Treatment for PSA screen-detected prostate cancer: what are the options?. <i>Nature Reviews Urology</i> , <b>2009</b> , 6, 132-4	5.5	
107	Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over. <i>Modern Pathology</i> , <b>2008</b> , 21, 54-9	9.8	28
106	Multiple newly identified loci associated with prostate cancer susceptibility. <i>Nature Genetics</i> , <b>2008</b> , 40, 316-21	36.3	722
105	SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?. <i>Nature Genetics</i> , <b>2008</b> , 40,	36.3	29
104	Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. <i>BJU International</i> , <b>2008</b> , 101, 547-55	5.6	44
103	Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumour. <i>BJU International</i> , <b>2008</b> , 101, 570-4	5.6	4



102	Is continent diversion using the Mitrofanoff principle a viable long-term option for adults requiring bladder replacement?. <i>BJU International</i> , <b>2008</b> , 102, 236-40	5.6	21
101	Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>BJU International</i> , <b>2008</b> , 102, 1122-31	5.6	26
100	Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?. <i>BJU International</i> , <b>2008</b> , 102, 1629-33	5.6	10
99	Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. <i>European Urology</i> , <b>2008</b> , 53, 1186-93	10.2	38
98	Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. <i>European Urology</i> , <b>2008</b> , 53, 777-84	10.2	16
97	The role of the Postgraduate Medical Education and Training Board (PMETB). <i>Surgery</i> , <b>2008</b> , 26, 403-407	0.3	
96	Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. <i>Lancet Oncology</i> , <b>2008</b> , 9, 445-52	21.7	192
95	Can we accurately identify men with low risk prostate cancer?. <i>Journal of Urology</i> , <b>2008</b> , 180, 1217-8	2.5	4
94	Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group. <i>Journal of Medical Ethics</i> , <b>2008</b> , 34, 37-40	2.5	16
93	Structural basis for the nuclear import of the human androgen receptor. <i>Journal of Cell Science</i> , <b>2008</b> , 121, 957-68	5.3	164
92	AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. <i>Cell Cycle</i> , <b>2008</b> , 7, 3525-33	4.7	11
91	Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 2052-61	4	134
90	Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 2325-36	4	80
89	Multiple loci with different cancer specificities within the 8q24 gene desert. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 962-6	9.7	283
88	High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 2527-34	12.9	32
87	Pro-neural transcription factors as cancer markers. <i>BMC Medical Genomics</i> , <b>2008</b> , 1, 17	3.7	24
86	Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. <i>Prostate</i> , <b>2008</b> , 68, 661-74	4.2	46
85	Alterations in beta-catenin expression and localization in prostate cancer. <i>Prostate</i> , <b>2008</b> , 68, 1196-205	4.2	61

84	RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. <i>Prostate</i> , <b>2007</b> , 67, 638-44	4.2	35
83	A role for neurotensin in bicalutamide resistant prostate cancer cells. <i>Prostate</i> , <b>2007</b> , 67, 190-202	4.2	25
82	Labeling and identification of LNCaP cell surface proteins: a pilot study. <i>Prostate</i> , <b>2007</b> , 67, 943-54	4.2	17
81	New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. <i>EMBO Reports</i> , <b>2007</b> , 8, 871-8	6.5	219
80	Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. <i>BJU International</i> , <b>2007</b> , 100, 826-9	5.6	47
79	Missing channels in two-colour microarray experiments: combining single-channel and two-channel data. <i>BMC Bioinformatics</i> , <b>2007</b> , 8, 26	3.6	4
78	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , <b>2007</b> , 8, 84	4.5	36
77	Reducing warm ischaemia time during laparoscopic partial nephrectomy: a prospective comparison of two renal closure techniques. <i>European Urology</i> , <b>2007</b> , 52, 1164-9	10.2	105
76	Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. <i>BMJ, The</i> , <b>2007</b> , 335, 1139	5.9	16
75	Non-invasive diagnosis <b>2007</b> , 39-49		
74	Fournier's gangrene. <i>Nature Reviews Urology</i> , <b>2006</b> , 3, 54-7; quiz 58		9
73	A model of the natural history of screen-detected prostate cancer. <i>British Journal of Cancer</i> , <b>2006</b> , 95, 1122-3	8.7	3
72	Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. <i>Journal of Urology</i> , <b>2006</b> , 176, 439-49	2.5	40
71	A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). <i>Contemporary Clinical Trials</i> , <b>2006</b> , 27, 413-9	2.3	19
70	Establishing a robotic prostatectomy programme: The impact of mentoring using a structured approach. <i>BJU International</i> , <b>2006</b> , 97, 1143-4	5.6	16
69	Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. <i>BJU International</i> , <b>2006</b> , 98, 777-82	5.6	35
68	Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. <i>Journal of Cell Biology</i> , <b>2005</b> , 170, 191-200	7.3	59
67	Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. <i>Nucleic Acids Research</i> , <b>2005</b> , 33, 13-26	20.1	133

66	Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 213-8	5.6	46
65	Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2004</b> , 13, 163-5	4	18
64	CD133, a novel marker for human prostatic epithelial stem cells. <i>Journal of Cell Science</i> , <b>2004</b> , 117, 3539-45	4.5	631
63	Putative involvement of the histone acetyltransferase Tip60 in ribosomal gene transcription. <i>Nucleic Acids Research</i> , <b>2004</b> , 32, 1654-65	20.1	35
62	Control of human PIRH2 protein stability: involvement of TIP60 and the proteasome. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 11696-704	5.4	51
61	Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 4874-84	12.9	66
60	Mucus production after transposition of intestinal segments into the urinary tract. <i>World Journal of Urology</i> , <b>2004</b> , 22, 178-85	4	20
59	Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. <i>Prostate</i> , <b>2004</b> , 59, 177-89	4.2	410
58	Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. <i>International Journal of Cancer</i> , <b>2004</b> , 108, 887-92	7.5	47
57	Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. <i>Urology</i> , <b>2004</b> , 64, 317-22	1.6	9
56	Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 1682-6	8.7	111
55	The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 46087-93	5.4	44
54	Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. <i>Contemporary Clinical Trials</i> , <b>2003</b> , 24, 272-82		106
53	Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. <i>BJU International</i> , <b>2003</b> , 91, 331-6; discussion 336	5.6	42
52	Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. <i>Oncogene</i> , <b>2003</b> , 22, 2466-77	9.2	183
51	Screening for prostate cancer. <i>Lancet, The</i> , <b>2003</b> , 361, 1122-8	40	145
50	Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). <i>Journal of Clinical Epidemiology</i> , <b>2003</b> , 56, 605-9	5.7	62
49	Including a $\text{Qo}$ active intervention arm in surgical trials is possible: evidence from the CLasP randomised trial. <i>Journal of Health Services Research and Policy</i> , <b>2003</b> , 8, 209-14	2.4	1

48	Adhesion of lymphocytes to bladder cancer cells: the role of the alpha(E)beta(7) integrin. <i>Cancer Immunology, Immunotherapy</i> , <b>2002</b> , 51, 483-91	7.4	15
47	Vitamin B12 malabsorption following bladder reconstruction or diversion with bowel segments. <i>ANZ Journal of Surgery</i> , <b>2002</b> , 72, 479-82	1	16
46	Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. <i>Journal of Pathology</i> , <b>2002</b> , 196, 292-9	9.4	102
45	Regulation of FGF8 expression by the androgen receptor in human prostate cancer. <i>Oncogene</i> , <b>2002</b> , 21, 5069-80	9.2	71
44	Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. <i>BMJ, The</i> , <b>2002</b> , 325, 766-70	5.9	388
43	Evaluation of dendritic cell immunogenicity after activation and chemical fixation: a mixed lymphocyte reaction model. <i>Journal of Immunotherapy</i> , <b>2002</b> , 25, 152-61	5	1
42	Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 25904-13	5.4	238
41	Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer. <i>American Journal of Pathology</i> , <b>2002</b> , 160, 693-700	5.8	30
40	Transurethral Prostate Resection, Noncontact Laser Therapy or Conservative Management in Men With Symptoms of Benign Prostatic Enlargement? An Economic Evaluation. <i>Journal of Urology</i> , <b>2002</b> , 168, 2476-2482	2.5	13
39	Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. <i>Oncogene</i> , <b>2001</b> , 20, 5359-65	9.2	38
38	Tip60 is a co-activator specific for class I nuclear hormone receptors. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 46841-8	5.4	74
37	Identification and isolation of human prostate epithelial stem cells based on $\alpha$ 1-integrin expression. <i>Journal of Cell Science</i> , <b>2001</b> , 114, 3865-3872	5.3	272
36	Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. <i>Molecular Endocrinology</i> , <b>2000</b> , 14, 1618-26		125
35	Prostate cancer: to screen or not to screen?. <i>Lancet Oncology, The</i> , <b>2000</b> , 1, 17-24	21.7	46
34	A RANDOMIZED TRIAL COMPARING TRANSURETHRAL RESECTION OF THE PROSTATE, LASER THERAPY AND CONSERVATIVE TREATMENT OF MEN WITH SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC ENLARGEMENT: THE CLAsP STUDY. <i>Journal of Urology</i> , <b>2000</b> , 164, 65-70	2.5	64
33	NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. <i>Journal of Urology</i> , <b>2000</b> , 163, 630-633	2.5	45
32	Tip60 is a nuclear hormone receptor coactivator. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 17599-604	5.4	202
31	FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. <i>Oncogene</i> , <b>1999</b> , 18, 2755-61	9.2	121

30	aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. <i>Journal of Pathology</i> , <b>1999</b> , 189, 564-9	9.4	47
29	Ryanodine receptors in human bladder smooth muscle. <i>Experimental Physiology</i> , <b>1999</b> , 84, 41-6	2.4	17
28	The immunohistochemical detection of cripto-1 in benign and malignant human bladder. <i>Journal of Pathology</i> , <b>1998</b> , 185, 108-11	9.4	9
27	Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. <i>Prostate</i> , <b>1998</b> , 37, 149-60	4.2	116
26	Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. <i>Prostate</i> , <b>1998</b> , 37, 223-9	4.2	68
25	Screening for prostate cancer. <i>Annals of Oncology</i> , <b>1998</b> , 9, 1289-92	10.3	6
24	Neuromodulation in bladder dysfunction. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>1998</b> , 10, 395-9	2.4	9
23	Fibroblast Growth Factor Receptor (FGFR). <i>Expert Opinion on Therapeutic Targets</i> , <b>1997</b> , 1, 173-175		
22	Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. <i>Urology</i> , <b>1997</b> , 50, 55-61	1.6	15
21	Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. <i>FEBS Letters</i> , <b>1997</b> , 405, 328-32	3.8	24
20	Keratinocyte growth factor expression in hormone insensitive prostate cancer. <i>Oncogene</i> , <b>1997</b> , 15, 1115-20	9.20	73
19	Basic science aspects of prostate cancer. <i>Seminars in Cancer Biology</i> , <b>1997</b> , 8, 21-7	12.7	31
18	The molecular pathology of urological malignancies. <i>Journal of Pathology</i> , <b>1997</b> , 183, 380-7	9.4	26
17	Effects of a new 5 alpha reductase inhibitor (episteride) on human prostate cell cultures. <i>Prostate</i> , <b>1997</b> , 32, 259-65	4.2	8
16	Transcutaneous Electrical Nerve Stimulation and Temporary S3 Neuromodulation in Idiopathic Detrusor Instability. <i>Journal of Urology</i> , <b>1996</b> , 155, 2005-2011	2.5	64
15	Conventional Urodynamics and Ambulatory Monitoring in the Definition and Management of Bladder Outflow Obstruction. <i>Journal of Urology</i> , <b>1996</b> , 155, 506-511	2.5	57
14	Surface localization of sacral foramina for neuromodulation of bladder function. An anatomical study. <i>European Urology</i> , <b>1996</b> , 29, 90-8	10.2	23
13	The morbidity of transurethral resection of the prostate. <i>Current Opinion in Urology</i> , <b>1996</b> , 6, 147-150	2.8	4

12	Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. <i>Nature Medicine</i> , <b>1996</b> , 2, 912-7	50.5	242
11	High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens?. <i>Carcinogenesis</i> , <b>1996</b> , 17, 601-4	4.6	19
10	Original Articles: Bladder Cancer: Long-Term Outcome Related to Epidermal Growth Factor Receptor Status in Bladder Cancer. <i>Journal of Urology</i> , <b>1995</b> , 153, 919-925	2.5	137
9	Transrectal ultrasound guided needle electromyography of the urethral sphincter in males. <i>Neurourology and Urodynamics</i> , <b>1995</b> , 14, 359-63	2.3	4
8	Detrusor contraction strength in men undergoing prostatectomy. <i>Neurourology and Urodynamics</i> , <b>1993</b> , 12, 109-121	2.3	12
7	Clean intermittent self catheterization. <i>International Urogynecology Journal</i> , <b>1993</b> , 4, 250-251	2	
6	Epidermal growth factor receptor and bladder cancer: a review. <i>Urologia Internationalis</i> , <b>1992</b> , 48, 365-71	1.9	65
5	The outcome of prostatectomy on chronic retention of urine. <i>Journal of Urology</i> , <b>1991</b> , 146, 1029-33	2.5	7
4	The epidermal growth factor receptor and the prognosis of bladder cancer. <i>Cancer</i> , <b>1990</b> , 65, 1619-25	6.4	299
3	Systematic Review and Meta-Analysis of the Associations Between Body Mass Index, Prostate Cancer, Advanced Prostate Cancer and Prostate Specific Antigen		1
2	A genetic risk score to guide age-specific, personalized prostate cancer screening		1
1	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations		1